Cautious On Biogen's Alzheimers Drug Due To Uncertainty Around Cost, Reimbursement, Access: Wedbush

Cautious on Biogen's Alzheimer’s drug due to uncertainty around cost, reimbursement, access: Wedbush

CNBC Television

Biogen Has Breakthrough Alzheimer's Drug

Bloomberg Television

Biogen shares drop as big clinics say they won't administer controversial Alzheimer's drug

CNBC Television

Breaking down the costs of Biogen's billion-dollar Alzheimer's drug

CNBC Television

Alzheimer's drug decision day: FDA to decide on Biogen and Eisai treatments

CNBC Television

Biogen Analyst Sees No Clear Growth Driver to Replace Alzheimer's Drug

Bloomberg Television

Big News in Alzheimer's Treatment A Drug Makes a Comeback

FDA approves Biogen Alzheimer's drug, first new therapy for the disease in nearly two decades

CNBC Television

FDA decision on experimental Alzheimer's drug expected this week

What’s The Controversy Behind Biogen’s Alzheimer’s Drug?

CNBC

Biogen shares drop despite positive Alzheimer's drug results

CNBC Television

Investors should have known better to blame Biogen for Alzheimer's drug failure: WSJ reporter

CNBC Television

FDA approves controversial Biogen Alzheimer's drug | DW News

FDA Approves First New Alzheimer's Drug in Nearly 20 Years

Bloomberg Quicktake

Why this analyst remains a 'skeptic' on Biogen's new Alzheimer's drug

CNBC Television

Eli Lilly CEO discusses FDA's approval of Biogen's new Alzheimer's drug

Evidence to approve Biogen's Alzheimer's drug was not 'sufficient': Penn's Dr. Jason Karlawi

CNBC Television

Biogen shares fall after it scraps Alzheimer's treatment

CNBC Television

Analyst on what Biogen's Alzheimer's drug means for the company

CNBC Television

FDA approves Biogen's Alzheimer's drug

CNBC Television